RTI Health Solutions

Pharma Unscripted

Technology EN ↓ 5 episodes

Pharma Unscripted explores how evidence is evolving across the biopharma landscape—and what that means for patients, access, and decision-making. Through expert-led conversations, the series examines how organizations are generating and applying evidence to bring meaningful therapies to the people who need them most. From patient-centered outcomes and real-world evidence to value demonstration and AI in medical communications, each episode breaks down the trends shaping how therapies move from development to real-world impact.

Author

RTI Health Solutions

Episodes

The First EU JCA Report: Methodological Learnings and Implications for Future Submissions 10.07.2026 23:31

What can manufacturers learn from the first EU JCA report? The first EU Joint Clinical Assessment report offers an early look at how evidence may be evaluated under the EU HTA Regulation. This episode explores key methodological learnings from the tovorafenib assessment and what they may mean for future submissions, especially in rare diseases. Key Topics: • PICO scope and consolidation • Systemat...

The Patient Experience: Evaluating Tolerability in Oncology Treatments 03.06.2026 26:05

Why is patient-centered evidence critical in oncology? As oncology treatments become more targeted and long-term, organizations need evidence that captures real-world patient experience. This episode explores how PROs, tolerability, and patient-centered evidence are shaping adherence, evidence strategy, and market access. Key Topics: Real-world patient experience Tolerability and treatment bur...

AI in Medical Communications: Why Human Expertise Still Matters 08.05.2026 20:35

This episode is part three of a three-part series featured on Fierce Pharma’s The Top Line podcast. AI is transforming medical communications, but it’s not replacing human expertise. In this episode of Pharma Unscripted , we explore how AI is being used across med comms workflows, from literature review to content creation, and where it introduces risk. Accuracy, context, and scientific integrity...

From Approval to Value: Evidence Storytelling, HEOR & Market Access 08.05.2026 17:41

This episode is part two of a three-part series featured on Fierce Pharma’s The Top Line podcast. Getting a therapy approved is only part of the journey, demonstrating its value is what drives access. In this episode of Pharma Unscripted , we explore how evidence storytelling is becoming critical in biopharma. From real-world evidence (RWE) to health economics and outcomes research (HEOR), organiz...

Putting Patients First: Patient-Centered Evidence & PROs in Biopharma 08.05.2026 28:03

This episode is part one of a three-part series featured on Fierce Pharma’s The Top Line podcast. What does it really mean to put patients first in biopharma? In this episode of Pharma Unscripted , we explore how patient-centered evidence, including patient-reported outcomes (PROs), is reshaping clinical development, regulatory expectations, and market access. As decision-makers look beyond tradit...